This company listing is no longer active
ZEAL Stock Overview
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Zealand Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.17.59 |
| 52 Week High | kr.32.94 |
| 52 Week Low | kr.9.93 |
| Beta | 1.34 |
| 1 Month Change | 4.02% |
| 3 Month Change | 36.46% |
| 1 Year Change | -38.92% |
| 3 Year Change | -29.50% |
| 5 Year Change | -5.94% |
| Change since IPO | -1.29% |
Recent News & Updates
Zealand Pharma announces private placement of 4.5M new shares
Oct 04Novo Nordisk to pay DKK25M upfront to Zealand Pharma in license deal for Zegalogue
Sep 07Zealand Pharma appoints CFO
Aug 24Recent updates
Zealand Pharma announces private placement of 4.5M new shares
Oct 04Novo Nordisk to pay DKK25M upfront to Zealand Pharma in license deal for Zegalogue
Sep 07Zealand Pharma appoints CFO
Aug 24Zealand Pharma to delist U.S.-listed shares, consolidate trading to Nasdaq Copenhagen
Aug 08Boehringer Ingelheim and Zealand Pharma get FDA fast track status for NASH treatment
Jun 02Zealand Pharma drops as dasiglucagon study fails to meet primary endpoint
Dec 15Zealand Pharma reports Q3 results
Nov 12Shareholder Returns
| ZEAL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.8% | 4.7% | 0.7% |
| 1Y | -38.9% | 2.7% | 23.9% |
Return vs Industry: ZEAL underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: ZEAL underperformed the US Market which returned -23.2% over the past year.
Price Volatility
| ZEAL volatility | |
|---|---|
| ZEAL Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZEAL's share price has been volatile over the past 3 months.
Volatility Over Time: ZEAL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 237 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.
Zealand Pharma A/S Fundamentals Summary
| ZEAL fundamental statistics | |
|---|---|
| Market cap | US$1.06b |
| Earnings (TTM) | -US$143.88m |
| Revenue (TTM) | US$38.71m |
27.4x
P/S Ratio-7.4x
P/E RatioIs ZEAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZEAL income statement (TTM) | |
|---|---|
| Revenue | kr.293.77m |
| Cost of Revenue | kr.112.39m |
| Gross Profit | kr.181.38m |
| Other Expenses | kr.1.27b |
| Earnings | -kr.1.09b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 10, 2022
| Earnings per share (EPS) | -23.60 |
| Gross Margin | 61.74% |
| Net Profit Margin | -371.73% |
| Debt/Equity Ratio | 70.9% |
How did ZEAL perform over the long term?
See historical performance and comparison